Marcelo Riberto, João Amaury Frances, Regina Chueire, Ana Cristina Ferreira Garcia Amorim, Denise Xerez, Tae Mo Chung, Lucia Helena Costa Mercuri, Sérgio Lianza, Eduardo Carvalho de Melo Rocha, Pascal Maisonobe, Thais Cuperman-Pohl, Patricia Khan
Botulinum toxin type A is approved for the focal treatment of spasticity; however, the effectiveness of abobotulinumtoxinA (aboBoNT-A) in patients with shoulder pain who have set reduced pain as a treatment goal is understudied. In addition, some patients encounter delays in accessing treatment programs; therefore, the suitability of aboBoNT-A for pain reduction in this population requires investigation. These factors were assessed in aboBoNT-A-naive Brazilian patients in a post hoc analysis of data from BCause, an observational, multicenter, prospective study (NCT02390206)...
November 20, 2022: Toxins